Heidelberg Pharma AG

Declaration of Voting Results & Voting Rights Announcements • Jul 6, 2010

News Details

Voting Rights Announcements | 6 July 2010 10:08

WILEX AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

WILEX AG / Release of an announcement according to Article 27a Section 1 of the WpHG

06.07.2010 10:08

Dissemination of a Voting Rights announcement, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Notification pursuant to section 27a para. 1 of the German Securities
Trading Act (WpHG)
Convenience Translation

UCB Pharma S.A., Brussels, Belgium, announced in a notice dated 9 June 2010
that its shareholdings had surpassed the threshold of 15% on 7 June 2010.
Pursuant to section 22 para. 1 sentence 1 no. 1 and 5 German Securities
Trading Act, the voting shares are attributable to the following companies:

1. UCB S.A., Brussels, Belgium
2. Financière de Tubize S.A., Brussels, Belgium

By notification dated 5 July 2010, both UCB Pharma S.A., UCB S.A. and
Financière de Tubize S.A. (hereinafter 'Notifying Parties') informed the
Company of the following in accordance with section 27a para. 1 German
Securities Trading Act concerning the aims underlying the purchase of the
voting rights and the origin of the funds used to purchase the voting
rights:

I. The investment is aimed at implementing strategic objectives and not at
generating a trading profit. Due to its specialisation in oncology, the
issuer is the ideal strategic partner for the development of an oncologic
product portfolio.

II. In general it is planned to participate in capital increases of the
company within the next twelve months to secure the strategic objective
pursuing the shareholding, if the economic and legal conditions are met. If
it should be seen as necessary and/or useful for securing the strategic
objective pursued with the shareholding, other arising possibilities to
increase the amount of voting rights will also be considered in the future.

III. Ms. Professor Dr. Iris Löw-Friedrich, Chief Medical Officer and
Executive Vice President Global Projects and Development, UCB S.A, is a
member of the issuers' Supervisory Board. Also in the future it is desired
to have an adequate - in relation to the size of shareholding -
representation in the issuer's Supervisory Board. Also, the possibilities
to exert influence, associated with the shareholding, on the appointment or
removal of members of the issuer's administrative, management and
supervisory bodies will be actively exercised.

IV. Presently, no essential change in the capital structure of the company,
in particular with regard to the equity and debt ratio and dividend policy,
is intended. If a respective question arises in the future and if it would
be seen as necessary and/or useful for the strategic objective pursuing the
shareholding, changes in the company's capital structure will be
considered.

V. The funds used for purchasing the voting rights are 100% financed by own
resources.

Munich, 6 July 2010

WILEX AG
Executive Management Board

06.07.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Deutschland
Internet: www.wilex.com

End of News DGAP News-Service

---